Updated Jul 16, 2026
Meckler Jeffrey A has filed 2 SEC Form 4 filings across 1 company in the last 90 days — selling. Lifetime open-market sales: $360K.
Jeffrey A. Meckler is the Chief Executive Officer and Director of Indaptus Therapeutics, Inc., a biotechnology company focused on developing immunotherapy treatments. He has held multiple roles within the company, contributing to its pre-clinical development efforts.
| Role | Insider |
|---|---|
| Notability | 20/100 |
| Date | Ticker | Company | Code | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-05-21 | TVTX | Travere Therapeutics, Inc. | A — Grant or award | 4.0K | $0.00 | |
| 2026-05-07 | TVTX | Travere Therapeutics, Inc. | S — Open-market sale | 8.0K | $45.00 | $360K |
| 2026-05-07 | TVTX | Travere Therapeutics, Inc. | M — Option exercise | 8.0K | $16.33 | $131K |
| 2025-12-29 | INDP | Indaptus Therapeutics, Inc. | A — Grant or award | 216.6K | $2.03 | $440K |
| 2025-07-27 | INDP | Indaptus Therapeutics, Inc. | A — Grant or award | 6.1K | $8.30 | $50K |
| 2024-11-26 | INDP | Indaptus Therapeutics, Inc. | A — Grant or award | 42.6K | $1.18 | $50K |
Jeffrey A. Meckler is the Chief Executive Officer and Director of Indaptus Therapeutics, Inc., a biotechnology company focused on developing immunotherapy treatments. He has held multiple roles within the company, contributing to its pre-clinical development efforts.…
2 primary Form 4 filings in the last 90 days, covering 1 company.
Recorded transactions: 0 open-market purchases () and 1 open-market sales ($360K) across all tracked filings.
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Open the live Meckler Jeffrey A profile on InsiderAlpha for real-time alerts, AI-scored trade ideas, and full transaction history.